Premium
Blunted vascular reactivity in healthy subjects at risk for type 2 diabetes mellitus
Author(s) -
Kadirvelu A.,
Heng N.,
Chan S.,
Choy A.,
Mustaffa M.,
Lang C.
Publication year - 2004
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2003.11.209
Subject(s) - medicine , diabetes mellitus , endothelial dysfunction , endocrinology , type 2 diabetes , endothelium , vascular disease , c reactive protein , cardiology , inflammation
Background Endothelial dysfunction is an important determinant of altered vascular reactivity and plays a major role in the genesis of vascular complications in diabetes (DM). However, it is not known, how early these abnormalities can be detected in those at risk of DM. The aim of our study was to evaluate the endothelial function, and its relation to C‐reactive protein (hsCRP), an inflammatiory marker in young first‐degree relatives (FDRs) of patients with DM. Methods We investigated 61 normotensive and normoglycemic subjects (mean age 31 ± 2 years; BMI<25) FDRs and compared with 20 age, sex and BMI‐matched control subjects (negative family history of diabetes) and 12 patients with type 2 DM without vascular complications. Endothelial function was assessed by high‐resolution vascular ultrasound and plasma hsCRP was assessed by integrated immonoturbidometric assay. Results Endothelium‐dependent dilatation was significantly reduced in FDRs (3.7 ± 0.8%; p<0.0001) and in subjects with type 2 DM (−2.54 ± 1.1%; p<0.0001) when compared to controls (12.6 ± 0.9%). No significant changes were noted in endothelium‐independent dilatation between FDRs, DM patients and controls. Plasma mean hsCRP level was significantly increased in FDRs (2.9 ± 4.1 mg/L; p<0.05) and in type 2 DM (3.7 ± 5.6 mg/L; p<0.05) when compared to controls (0.7 ± 1.2 mg/L). Conclusion Our study demonstrates a significant impairment of vascular reactivity in FDRs, who also have elevated levels plasma hs‐CRP. Clinical Pharmacology & Therapeutics (2004) 75 , P55–P55; doi: 10.1016/j.clpt.2003.11.209